Enliven Therapeutics, Inc. (ELVN) |
|
17.31 -0.78 (-4.31%)
|
05-31 13:20 |
|
Open: |
17.98 |
Pre. Close: |
18.09 |
|
High:
|
19.73 |
Low:
|
17.15 |
|
Volume:
|
48,638 |
Market Cap:
|
712(M) |
|
|
|
Technical analysis |
as of: 2023-05-31 12:47:38 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 23.24  One year: 25.22 |
| Support: |
Support1: 17.14 Support2: 14.26 |
| Resistance: |
Resistance1: 19.9 Resistance2: 21.6 |
| Pivot: |
19.55 |
| Moving Average: |
MA(5): 18.87 MA(20): 19.47
MA(100): 15.1  MA(250): 7.54 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 18.3 %D(3): 30.9 |
| RSI: |
RSI(14): 35.8 |
| 52-week: |
High: 24.79 Low: 1 |
| Average Vol(K): |
3-Month: 124 (K) 10-Days: 124 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ELVN ] has closed below the lower bollinger band by 12.3%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 37.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
20.16 - 20.3 |
20.3 - 20.41 |
|
Low:
|
17.38 - 17.55 |
17.55 - 17.68 |
|
Close:
|
17.85 - 18.08 |
18.08 - 18.27 |
|
Company Description |
|
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado. |
Headline News |
Thu, 11 May 2023
Enliven Therapeutics Highlights Business Achievements and ... - GlobeNewswire
Tue, 11 Apr 2023
3 Stocks in the Limelight on New Analyst Coverage - Yahoo Finance
Thu, 23 Mar 2023
5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science - Yahoo Finance
Thu, 23 Mar 2023
Chronic Myeloid Leukemia Market to Exhibit Significant Growth as ... - GlobeNewswire
Fri, 03 Mar 2023
Veris Residential and Rogers Stock See Action From Activist Investors - Barron's
Thu, 23 Feb 2023
Enliven Therapeutics Closes Merger with Imara and Private ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
41 (M) |
| Shares Float |
1 (M) |
|
% Held by Insiders
|
2.8 (%) |
|
% Held by Institutions
|
53.5 (%) |
|
Shares Short
|
2,080 (K) |
|
Shares Short P.Month
|
877 (K) |
Stock Financials |
|
EPS
|
-0.93 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-6.35 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-24.7 |
|
Return on Equity (ttm)
|
-42 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.94 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-32 (M) |
|
Levered Free Cash Flow
|
-17 (M) |
Stock Valuations |
|
PE Ratio
|
-18.81 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-2.73 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-22.17 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
